Surgery Partners’ (SGRY) Overweight Rating Reaffirmed at Cantor Fitzgerald

Surgery Partners (NASDAQ:SGRY)‘s stock had its “overweight” rating reaffirmed by stock analysts at Cantor Fitzgerald in a note issued to investors on Tuesday,Benzinga reports. They presently have a $18.00 price target on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 12.85% from the company’s previous close.

Other equities research analysts have also recently issued reports about the company. Jefferies Financial Group reaffirmed a “buy” rating and set a $17.00 price objective on shares of Surgery Partners in a research note on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Surgery Partners in a research note on Tuesday, May 26th. Finally, Zacks Research upgraded shares of Surgery Partners from a “hold” rating to a “strong-buy” rating in a research report on Thursday, June 4th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $19.80.

Surgery Partners Price Performance

Shares of SGRY stock opened at $15.95 on Tuesday. The firm has a market cap of $2.09 billion, a price-to-earnings ratio of -26.58, a PEG ratio of 4.64 and a beta of 1.92. The company has a quick ratio of 1.69, a current ratio of 1.86 and a debt-to-equity ratio of 1.17. Surgery Partners has a 12 month low of $11.41 and a 12 month high of $24.10. The stock has a 50-day moving average price of $15.49 and a 200 day moving average price of $14.43.

Surgery Partners (NASDAQ:SGRY) last released its earnings results on Monday, August 10th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.04. The firm had revenue of $848.90 million during the quarter, compared to analyst estimates of $830.03 million. Surgery Partners had a negative net margin of 2.28% and a positive return on equity of 1.04%. The business’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.17 EPS. Research analysts expect that Surgery Partners will post 0.25 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in SGRY. BlackRock Inc. bought a new position in shares of Surgery Partners in the 2nd quarter valued at about $104,857,000. Deutsche Bank AG acquired a new stake in Surgery Partners during the 2nd quarter valued at $1,495,000. Bank of New York Mellon Corp acquired a new position in shares of Surgery Partners in the second quarter valued at $5,379,000. State of Wyoming acquired a new stake in shares of Surgery Partners during the 2nd quarter worth about $262,000. Finally, Bank of America Corp DE grew its stake in Surgery Partners by 97.9% in the 1st quarter. Bank of America Corp DE now owns 1,239,982 shares of the company’s stock valued at $14,781,000 after buying an additional 613,505 shares during the last quarter.

More Surgery Partners News

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Second-quarter revenue rose 2.7% year over year to $848.9 million, exceeding the $830.0 million consensus estimate. Adjusted earnings were $0.10 per share, ahead of the $0.06 analyst estimate and the primary reason for the favorable market reaction. Surgery Partners Beats Q2 Sales Expectations
• Positive Sentiment: Same-facility revenue increased 5.0%, driven mainly by a 4.8% increase in revenue per case, while same-facility cases rose 0.3%. Year-to-date revenue was up 3.6% to $1.66 billion. Surgery Partners Reports Q2 Results
• Positive Sentiment: Management reaffirmed full-year 2026 revenue guidance of $3.35 billion to $3.45 billion and adjusted EBITDA of at least $530 million, excluding the pending Idaho Falls divestiture. The transaction is expected to improve cash conversion and reduce leverage if completed. Surgery Partners Announces Q2 Results and Reaffirms Guidance
• Positive Sentiment: Brokerages’ consensus price target is $21.60, above the stock’s recent trading level, suggesting analysts see meaningful potential upside. Surgery Partners Receives Consensus Target Price
• Neutral Sentiment: The company ended the quarter with $216.7 million in cash, $617.8 million of revolver capacity and approximately 4.4x net debt to EBITDA, leaving balance-sheet management important for investors.
• Negative Sentiment: GAAP net loss attributable to Surgery Partners widened to $15.0 million from $2.5 million a year earlier. Adjusted EBITDA declined to $125.2 million from $129.0 million, reducing the margin to 14.7% from 15.6%. Operating cash flow also fell to $59.3 million from $81.3 million. Surgery Partners Q2 Earnings Snapshot
• Negative Sentiment: Reported insider activity shows executives made no open-market purchases and completed multiple sales during the past six months, a potentially cautious signal.

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.